Full-Time

Head of Analytical Development and Quality Control

Confirmed live in the last 24 hours

Metagenomi

Metagenomi

201-500 employees

Develops genome editing tools for therapeutics

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$220k - $320kAnnually

+ Equity + Bonuses + Full range of benefits

Senior, Expert

Oakland, CA, USA

Position located at the Emeryville, California headquarters.

Category
Bioinformatics
Computational Biology
Public Health
Biology & Biotech
Requirements
  • Ph.D. in Biochemistry, Analytical Chemistry, Microbiology, Genetics, or a related life sciences discipline.
  • At least 15 years of experience in analytical development and quality control within the biotech industry.
  • Industry experience managing scientific teams with a proven ability to lead and grow strong technical teams.
  • Extensive industry experience with nucleic acids, viral vectors, lipid nanoparticles, and complex biologicals.
  • Demonstrated expertise in cGMP regulations, ICH guidelines, and USP standards, and their application in clinical development and commercialization.
Responsibilities
  • Establish and lead the ASQC strategy, including tactics, timelines, budgets, and resource allocation.
  • Build and mentor high-performing teams, proactively identify and resolve critical analytical issues, and support talent development and engagement.
  • Develop and qualify phase-appropriate methods for release, characterization, and stability of complex biologicals, utilizing state-of-the-art technologies and approaches.
  • Oversee the qualification, transfer, and execution of analytical and bioanalytical assays, ensuring compliance with cGMP regulations and ICH guidelines.
  • Provide strategic oversight for the design, establishment, and execution of processes and procedures for the lifecycle management of analytical methods for clinical and commercial product testing.
  • Drive the strategy for product quality assessment, analytical comparability, and characterization.
  • Author and review relevant CMC sections of regulatory submissions, serving as an analytical subject matter expert in regulatory interactions.
  • Draft guidelines and set release and stability specifications for clinical-stage and commercial programs.
  • Partner with internal and external stakeholders to lead Quality Target Product Profile and product characterization strategy, enhancing process-to-product understanding and supporting process development and characterization.

Metagenomi focuses on developing new genome editing tools for genetic medicine. The company explores natural environments to find undiscovered genetic material, which is then sequenced and engineered into potential therapeutics. By utilizing artificial intelligence and high-throughput screening, Metagenomi can quickly analyze billions of proteins to identify effective genome editing tools. This approach sets them apart from competitors who may rely on more traditional methods of discovery. The goal of Metagenomi is to create curative treatments for diseases through advanced gene editing technologies, ultimately benefiting healthcare providers and patients.

Company Stage

IPO

Total Funding

$366.1M

Headquarters

Emeryville, California

Founded

2016

Growth & Insights
Headcount

6 month growth

-4%

1 year growth

-2%

2 year growth

62%
Simplify Jobs

Simplify's Take

What believers are saying

  • Metagenomi's partnerships with high-profile companies like Bayer and Ionis highlight strong industry validation and potential for significant financial backing.
  • The company's ability to regain full control over its base editing technology and RNA-mediated integration systems post-Moderna partnership allows for greater strategic flexibility.
  • Despite a rocky IPO, Metagenomi's innovative approach and substantial Series B funding indicate strong growth potential in the long term.

What critics are saying

  • The departure of key executives like the Chief Scientific Officer shortly after the IPO could signal internal instability and affect investor confidence.
  • The termination of the $3 billion deal with Moderna raises concerns about the company's ability to secure and maintain strategic partnerships.

What makes Metagenomi unique

  • Metagenomi leverages metagenomics to source novel genetic material from unexplored natural environments, setting it apart from competitors who rely on more conventional methods.
  • The integration of AI and high-throughput screening allows Metagenomi to rapidly identify highly efficient and specific genome editing tools, providing a technological edge.
  • Their focus on creating a diverse genome editing toolbox capable of correcting any genetic mutation offers a unique value proposition in the genetic medicine market.

Help us improve and share your feedback! Did you find this helpful?